Estrus after treatment with Syncro-Mate B* in ovariectomized heifers is dependent on the injected estradiol valerate

A series of experiments was conducted to determine why ovariectomized heifers exhibit estrus after they are treated with the estrus synchronization product, Syncro-Mate B(*) (SMB). In Experiment 1, 23 of 40 (58%) ovariectomized heifers exhibited estrus after treatment with SMB. The mean concentration of estradiol-17beta (E(2)) in serum was lower (P < 0.001) before treatment than after implant removal in ovariectomized heifers treated with SMB. Six of 10 heifers from which serum was collected to determine concentrations of LH exhibited estrus and 5 of 6 had a surge of LH in serum after implant removal. In Experiment 2, when no estradiol valerate (EV) was given or when the norgestomet implant period was extended from 9 to 18 d, no heifer exhibited estrus after implant removal. The mean concentration of E(2) for 3 d after implant removal was lower (P < 0.001) in ovariectomized heifers with implants for 18 d versus those with implants for 9 d and was also lower (P < 0.001) in ovariectomized heifers treated only with norgestomet compared with those receiving the standard SMB treatment. When estradiol-17beta was substituted for EV in the SMB treatment, serum E(2) was lower (P < 0.001) after implant removal than in heifers receiving the standard SMB treatment. Experiment 3 demonstrated that combining a norgestomet implant or implant plus a 3-mg injection of norgestomet with EV did not alter concentrations of E(2) in serum on the days when synchronized estrus would be expected following SMB treatment. The results indicate that the SMB-induced estrus in ovariectomized heifers is dependent upon EV in the SMB treatment. Apparently, EV elevates the concentration of E(2) in serum, and the E(2) remains sufficiently high to induce estrus after implant removal.     

Induction of ovulatory estrus and fertility in non-cycling buffaloes with norgestomet during low breeding season

Field trials were designed to evaluate use of norgestomet treatment to induce ovulatory estrus in non-cycling buffalo cows and heifers during low breeding season. Twenty-five buffalo cows and 50 heifers under village management were given a 9-day treatment with a polymer implant containing 6 mg norgestomet with IM injections of 5 mg estradiol valerate + 3 mg norgestomet at the time of implantation and 600 IU PMSG when the implant was removed. Fifty animals served as controls without any treatment. Seventy-four treated animals showed estrus during the period between 36 to 80 hours after removal of the implant. Twenty-five buffalo cows and 40 heifers that could be further followed up were inseminated twice at 8-hour intervals, 12 hrs after induction of estrus with chilled semen by recto-vaginal method. Of these, 15 (23.1%) conceived, 9 (36%) among buffalo cows and 6 (15%) among heifers. Fourteen buffalo cows and 30 heifers that did not conceive manifested cyclic estrus at an interval of 22.4 and 20.6 days. The conception rate in the cyclic estrus was 57% and 23.3%, respectively, for buffalo cows and heifers. The overall conception rate over two inseminations was 46.2%, 68% in buffalo cows and 32.5% in heifers. In the control group, five (10%) showed spontaneous estrus and two (40%) conceived during the period of the experiment.     

Effect of estradiol valerate on ovarian follicle dynamics and superovulatory response in progestin-treated cattle

Three experiments evaluated the effects of estradiol valerate (EV) on ovarian follicular and CL dynamics, intervals to estrus and ovulation, and superovulatory response in cattle. Experiment 1 compared the efficacy of two norgestomet ear implants (Crestar and Syncro-Mate B; SMB) for 9 d (with PGF at implant removal), combined with either 5 mg estradiol-17beta and 100 mg progesterone (EP) or 5 mg EV and 3mg norgestomet (EN) im at the time of implant insertion on CL diameter and follicular wave dynamics. Ovaries were monitored by ultrasonography. There was no effect of norgestomet implant. Diameter of the CL decreased following EN treatment (P < 0.01). Mean (+/- S.D.) day of follicular wave emergence (FWE) was earlier (P < 0.0001) and less variable (P < 0.0001) in EP- (3.6 +/- 0.5 d) than in EN- (5.7 +/- 1.5 d) treated heifers. Intervals from implant removal to estrus (P < 0.001) and ovulation (P < 0.01) were shorter in EN- (45.7 +/- 11.7 and 74.3 +/- 12.6 h, respectively) than in EP- (56.4 +/- 14.1 and 83.3 +/- 17.0 h, respectively) treated heifers. Experiment 2 compared the efficacy of EP versus EN in synchronizing FWE for superovulation in SMB-implanted cows. At random stages of the estrous cycle, Holstein cows (n = 78) received two SMB implants (Day 0) and were randomly assigned to receive EN on Day 0 or EP on Day 1. Folltropin-V treatments were initiated on the evening of Day 5, with PGF in the morning and evening of Day 8, when SMB were removed. Cows were inseminated after the onset of estrus and embryos were recovered 7 d later. Non-lactating cows had more CL (16.7 +/- 11.3 versus 8.3 +/- 4.9) and total ova/embryos (14.7 +/- 9.5 versus 7.9 +/- 4.6) than lactating cows (P < 0.05). EP-treated cows tended (P = 0.09) to yield more transferable embryos (5.6 +/- 5.2) than EN-treated cows (4.0 +/- 3.7). Experiment 3 compared the effect of dose of EV on ovarian follicle and CL growth profiles and synchrony of estrus and ovulation in CIDR-treated beef cows (n = 43). At random stages of the estrous cycle (Day 0), cows received a CIDR and no further treatment (Control), or an injection of 1, 2, or 5 mg im of EV. On Day 7, CIDR were removed and cows received PGF. Follicular wave emergence occurred within 7 d in 7/10 Control cows and 31/32 EV-treated cows (P < 0.05). In responding cows, interval from treatment to FWE was longer (P < 0.05) in those treated with 5 mg EV (4.8 +/- 1.2 d) than in those treated with 1 mg (3.2 +/- 0.9 d) or 2 mg (3.4 +/- 0.8 d) EV, while Control cows were intermediate (3.8 +/- 2.0 d). Diameter of the dominant follicle was smaller (P < 0.05) at CIDR removal and tended (P = 0.08) to be smaller just prior to ovulation in the 5 mg EV group (8.5 +/- 2.2 and 13.2 +/- 0.6 mm, respectively) than in the Control (11.8 +/- 4.6 and 15.5 +/- 2.9 mm, respectively) or 1mg EV (11.7 +/- 2.5 and 15.1 +/- 2.2 mm, respectively) groups, with the 2mg EV group (10.7 +/- 1.5 and 14.3 +/- 1.7 mm, respectively) intermediate. Diameter of the dominant follicle at CIDR removal was less variable (P < 0.01) in the 2 and 5mg EV groups than in the Control group, and intermediate in the 1mg EV group. In summary, treatment with 5mg EV resulted in a longer and more variable interval to follicular wave emergence than treatment with 5mg estradiol-17beta, which affected preovulatory dominant follicle size following progestin removal, and may have also affected superstimulatory response in Holstein cows. Additionally, 5 mg EV appeared to induce luteolysis in heifers, reducing the interval to ovulation following norgestomet removal. Conversely, intervals to, and synchrony of, follicular wave emergence, estrus and ovulation following treatment with 1 or 2 mg EV suggested that reduced doses of EV may be more useful for the synchronization of follicular wave emergence in progestogen-treated cattle.     

Reproductive performance of synchronized beef cows as affected by inhibition of suckling with nose tags or temporary calf removal

A study was conducted to determine whether presence of the calf during suckling inhibition influences the response to estrus synchronization in beef cows. Angus or Hereford cows (n=89) were administered Syncro-Mate-B (SMB), which consisted of a 6-mg norgestomet ear implant (in situ 9 d) in conjunction with 5 mg of estradiol valerate and 3 mg (im) of norgestomet. Cows were allotted by breed, body condition, stage of the estrous cycle, parity and date of parturition to 1 of 3 treatments: 48-h calf removal; ad libitum suckling; or inhibition of suckling with a nose tag for 48 h. Calves were weighed at time of SMB implant removal, 48 h later and at weaning. Cows were mated via AI approximately 12 h after detection of estrus during a 30-d period after implant removal followed by a natural service period of 35 d. At 48 h after implant removal, calf removal and nose tag calves had lost an average of 3.6 and 0.9 kg, respectively, while the suckled calves gained 1.8 kg (P < 0.01). Mean calf weight at weaning did not differ among treatments. Synchronized estrous response (within 5 d of implant removal) was not different among treatments. Pregnancy rate for cows exhibiting a synchronized estrus (5 d AI) for calf removal, nose tag and suckled cows was 76, 48 and 48%, respectively (P>0.10). Treatment did not affect the 30-d AI or overall 65-d pregnancy rate. In this study, there were no differences observed in the percentage of synchronized or pregnant cows following suckling inhibition by either a nose tag or calf removal. Transient reductions of calf body weight during the 48-h calf removal period did occur in both the nose tag and calf removal groups.     

Effect of norgestomet on peripheral levels of progesterone and estradiol-17beta in beef cows

Peripheral levels of progesterone and estradiol 17beta were quantified in 27 cycling cows following administration of a single Hydron ear implant (G. D. Searle and Co.) containing 2, 4 or 6 mg norgestomet or controls which received no implant. Implants were inserted subcutaneously in the ear on day 15 of the estrous cycle (day of estrus = day 0) and removed 9 days later. The 4 mg (seven of seven cows) and 6 mg (six of six cows) implants suppressed estrus; however, three of eight cows in the 2 mg group exhibited estrus prior to implant removal. The 6 mg implant group had a significantly longer interval from implant removal to estrus than either the 2 or 4 mg group. Failure to detect differences in the rate at which progesterone declined indicated norgestomet treatment did not affect normal corpus luteum regression. Estradiol levels rose at a similar rate approaching estrus in all treatments. There was no indication of increased endogenous estradiol levels due to norgestomet treatment.     

Comparison of Melengestrol Acetate-Prostaglandin F(2)alpha to Syncro-Mate B for estrus synchronization in beef heifers

Three hundred and ten yearling heifers of various breeds were used in five trials to compare two estrus synchronization treatments. Treatment 1 consisted of Melengestrol Acetate-Prostaglandin F(2)alpha (MGA-PGF(2)alpha). Heifers were fed 0.5 mg MGA/head/d for 14 to 16 d. Sixteen or 17 d after the final MGA feeding, heifers were injected i.m. with 25 mg PGF(2)alpha. Treatment 2 consisted of Syncro-Mate B (SMB). Heifers were given a 9-d norgestomet implant plus an injection containing 3 mg norgestomet and 5 mg estradiol valerate i.m. at implant insertion. Heifers were observed for estrus at 6-h intervals for 120 h after the end of treatments and were artificially inseminated 12 to 18 h after observed estrus. Heifers synchronized with MGA-PGF(2)alpha and SMB had a similar (P > 0.10) estrous response (83.4 vs 90.2%) and a similar (P > 0.10) degree of synchrony (71.8 vs 79.0%) following treatment. However, the synchronized conception rate (68.7 vs 40.6%) and the synchronized pregnancy rate (57.3 vs 36.6%) were higher (P < 0.01) in MGA-PGF(2)alpha than SMB heifers. Breeding season pregnancy rates were similar in both treatment groups. Heifers in both groups that were classified as cycling prior to initiation of treatment had improved reproductive performance following synchronization compared with those classified as noncycling. Based on higher synchronized conception and pregnancy rates and lower labor requirements and drug costs, the MGA-PGF(2)alpha system appears to be a better method to synchronize estrus in beef heifers than the SMB system.     

Effect of steroids and/or 48 HR calf removal on serum luteinizing hormone concentrations in anestrous beef cows

Serum luteinizing hormone (LH) concentrations were quantified in 27 thin, anestrous cows with suckling calves in each of three treatment groups: Syncro-Mate-B (SMB), 48 hr calf removal (CR), and SMB plus CR (SMB + CR). The SMB treatment consisted of a 9 day ear implant containing 6 mg norgestomet and an intramuscular injection containing 3 mg norgestomet and 6 mg estradiol valerate given at the time of implant placement. In the SMB + CR group, CR began at the time of implant removal (0 hr). Blood samples were collected every 4 hr via puncture of a tail vessel beginning 12 hr prior to implant and/or CR and continued for 72 hr thereafter. Before implant and/or CR (-12 to 0 hr), LH concentrations were higher (P<.01) in the CR (1.1 ng/ml) group than in the SMB (.6 ng/ml) and SMB + CR (.8 ng/ml) groups. Following implant and/or CR (4 to 48 hr), LH concentrations increased (P<.01) in the CR (1.8 ng/ml) and SMB + CR (1.3 ng/ml) groups, but remained unchanged in the SMB (.7 ng/ml) group. Furthermore, LH concentrations were higher (P<.05) in the CR group compared to the SMB + CR group. Circulating concentrations of LH declined (P<.01) to 1.2 ng/ml in the CR group following calf return, but remained unchanged in the other two groups. Although more (P<.01) cows in the SMB and SMB + CR groups were detected in estrus than in the CR group, there was no difference (P.10) in the number of cows ovulating between the three treatment groups. These results suggest that CR will increase circulating LH concentrations by 24 hr post CR and that SMB may partially suppress the CR induced LH release following implant and calf removal.     

Peripheral progesterone levels in pregnant and non-pregnant heifers following use of HCG.

Progesterone concentration in jugular blood of bred beef heifers was determined on days 9 and 16 in two trials. Human chorionic gonadotrophin (HCG) was administered to some of the heifers in each trial in an attempt to improve pregnancy percentage.In Trial 1, 183 heifers were divided into a control group and three groups of animals which were subjected to a 9-day estrous synchronization treatment prior to breeding. The treatment consisted of an ear implant containing 17 α acetoxy-11-beta-methyl 17 nor preg 4-ene 3, 20 dione (norgestomet) left in place for 9 days and an injection of 5 mg estradiol valerate (EV) and 3 mg of norgestomet given at the time of implantation. The heifers in one group received .25 mg estradiol-17β at time of implant removal; heifers in the 2nd group received 1500 IU of HCG in 5% beeswax and 95% sesame oil at breeding time, while heifers in the 3rd group received a placebo injection containing 5% beeswax and 95% sesame oil at breeding time. No differences in serum levels of progesterone were observed (P>0.5) between treatments or between pregnant and non-pregnant heifers on day 9 or 16 (P>.05). Pregnancy percentage in heifers receiving HCG was similar to that noted in the control heifers or the placebo injected heifers while injection of estradiol 17β decreased the proportion of heifers which became pregnant.In trial 2, 58 heifers which had been bred 1 or 2 times without becoming pregnant were divided into a control group and a group in which heifers received 1000 IU of HCG 96 hr. after observed estrus. In heifers receiving HCG, serum levels of progesterone were higher (P<.01), on day 9 and 16 post estrus than in controls but no difference in serum progesterone was noted (P>.05) between pregnant and non-pregnant heifers on day 9 or 16. The proportion pregnant did not differ (P>.05) between heifers receiving HCG and control heifers.     

Plasma progesterone profiles and fertility status of anestrus Zebu cattle treated with norgestomet-estradiol-eCG regimen

Zebu cattle are notorious for poor fertility characterized by late maturity and long intercalving intervals attributed to a variety of factors, including genetic, nutritional and climatic. The aim of the present investigation, therefore, was to induce fertile estrus in acyclic pubertal heifers and postpartum anestrous Zebu cows by hormonal intervention. Pubertal Hariana and Sahiwal anestrous heifers (n=51) and postpartum cows (n=55) were either assigned a placebo (controls, N=6 for each breed and parity) or treated with 10-d norgestomet (3 mg) subcutaneous ear implants, with an initial injection of 3 mg, im norgestomet + 5 mg estradiol valerate, followed by 500 IU eCG at implant withdrawal (NOR-treated groups). Jugular venous plasma samples were obtained from a total of 28 animals (controls : 4 heifers and 4 cows; NOR-treated : 12 heifers and 8 cows) on Days 0 (implant insertion), 3, 7, 9 and Day 10 (implant withdrawal), every 12 h on Days 11 and 12, and then once daily on Days 17, 24 and 31. All the samples were assayed for progesterone. Almost all (97%) heifers and 81% cows were induced to estrus, the majority (92% heifers and 79% cows) within 120 h of implant removal. Synchrony of the induced estrus was better in cows, but interval to estrus and estrus duration were significantly longer in heifers (P<0.05). Post-treatment fertility, based on Day 28 nonretum rate, first service, and overall conception rates, was better in heifers (78.9, 60.5 and 73.7%, respectively) than cows (77.1, 48.6 and 62.9%, respectively), but the differences were significant only for the overall pregnancy rate (71.8% for heifers and 51.2% for cows; P<0.05). Low pre-treatment plasma progesterone values (<0.5ng/mL) were consistent with ovarian inactivity, confirming the true anestrus status of experimental animals. Controls failed to exhibit estrus and maintained low progesterone concentrations throughout the study. In treated animals, high progesterone values from Day 17 onwards suggested ovulatory estrus. These early luteal phase progesterone concentrations in nonpregnant (P=0.06) and nonpregnant, nonretum (P<0.05) animals were low in comparison with those of pregnant animals. Good fertility resulting from breeding according to estrus, inspite of variable intervals to estrus and estrus duration, advocates its advantage over fixed-time insemination in norgestomet-treated anestrous Zebu cattle.     

Norgestomet implants maintain pregnancy in ovariectomized heifers

Fifty-five heifers were synchronized with norgestomet and estradiol valerate and artificially inseminated approximately 48 h after the removal of norgestomet implants. Ten days after Al, 15 of the heifers were ovariectomized and then two 15 mg norgestomet/silicone implants were implanted subcutaneously on the convex surface of the ear. The norgestomet/silicone implants were changed every 55 +/-4 d (mean range) thereafter, and the last set of implants was removed 273 d after Al. At 44 d after Al, 65% (26/40) of the control heifers and 53% (8/1 5) of the ovariectomized heifers with norgestomet implants were pregnant (P > 0.10). Two pregnancies were lost in ovariectomized heifers treated with norgestomet (44 to 96 d after Al) and a third pregnancy failed in a heifer that lost 1 of 2 implants 65 to 96 d after Al. Ninety-six days after Al implants were removed from 2 pregnant ovariectomized heifers with norgestomet implants. These 2 heifers were open at 116 d after Al. All 3 ovariectomized heifers with norgestomet implants pregnant at 273 d after Al calved an average of 41 h after the removal of the last set of norgestomet/silicone implants. Dystocia (P < 0.05), retention of fetal membranes (P < 0.01), and calf mortality (P < 0.01) were higher for the ovariectomized heifers with norgestomet implants than for the control heifers.     

Use of short-term progestin treatment to resynchronize the second estrus following synchronized breeding in beef heifers

Two trials were conducted to evaluate the efficacy of short-term progestin administration to resynchronize the second estrus after artificial insemination in yearling beef heifers. In Trial 1 crossbred yearling heifers (n = 208) were synchronized with Syncro-Mate-B (SMB) and artificially inseminated (AI) between 48 and 54 h following implant removal. Implant removal is defined as Day 1. Following AI, the heifers were randomly assigned to 1 of 2 experimental groups. Group 1 heifers were fed melengestrol acetate (MGA) daily from Day 17 to 21 at a rate of 0.5 mg/head, while Group 2 control received no exogenous progestin during this period. Synchrony of estrus was defined as the 3-d period in which the highest number of heifers expressed behavioral estrus in each group. There was no difference (P < 0.05) in the pregnancy rate during the second estrus due to MGA supplementation. More MGA-treated heifers (P < 0.01) expressed estrus in a 3-d period than the controls. In Trial 2, yearling heifers (n = 108) were synchronized with 2 injections of PGF(2alpha) (second PGF(2alpha) injection is designated as Day 1) administered 14 d apart with AI 12 h after the onset of behavioral estrus. The heifers were then randomly assigned to 1 of the following 3 treatment groups after initial AI: 1) MGA fed at 0.5 mg/head daily from Days 17 to 21; 2) norgestomet administered in 6.0-mg implants from Days 17 to 21; 3) untreated control heifers. Blood samples were collected on Day 21 and analyzed for progesterone (P(4)). Elevated P(4) (> 1 ng/ml) on Day 21 indicated pregnancy to the first insemination. Synchrony among the 3 groups of heifers was similar (P > 0.10); however, the second estrus was less (P < 0.05) variable in the MGA and norgestomet treated heifers. During the resynchronized second estrus, conception rates were not affected by progestin treatment (MGA 40%, norgestomet 64%, and control 62%; P > 0.10). However, a proportion of heifers treated MGA 10% 4 36 and norgestomet 3% 1 36 expressed behavioral estrus during second estrus even though they were diagnosed as pregnant from first service by elevated P(4) levels on Day 21. We conclude that short-term use of progestin from Days 17 to 21 following AI causes closer synchrony of estrus; however, inseminating pregnant heifers that exhibit behavioral estrus may cause abortion.     

Effect of estrous cycle stage at Syncro-Mate B treatment on conception and time to estrus in cattle

Two trials involving 85 heifers and 67 cows were conducted to determine the effect of estrous cycle stage at the time of Syncro-Mate-B((R)) (SMB) treatment on interval to estrus following implant removal and on conception rate at the synchronized estrus. In Trial 1, 57 beef and 28 dairy heifers were treated with SMB on each representative day of a 22-d estrous cycle (estrus = Day 0). Beef heifers were artificially inseminated approximately 48 h after implant removal, whereas dairy heifers were inseminated 0 to 12 h after detection of estrus. Inseminations were scored by the inseminator according to their difficulty. Interval to the onset of estrus was not different between heifers treated early ( Day 11) in the cycle (35.2 +/- 7.2 h). Conception rate at the synchronized estrus was slightly higher in early-cycle heifers (22 47 = 47% ) compared to late-cycle heifers (14 38 = 37% , P = 0.2). Heifers that were difficult to inseminate had lower (P < 0.01) conception rates (2 11 = 18% ) at the synchronized estrus than heifers considered normal (21 51 = 41% ) or easier than normal to inseminate (13 23 = 57% ). In Trial 2, of the 131 beef cows synchronized, 67 that were estimated to be either early or late in the estrous cycle by progesterone analysis were utilized. Cows were treated with SMB and inseminated without regard to estrus 48-h after implant removal. Inseminations were scored as in Trial 1. Calves were separated from cows from the time of implant removal to insemination. Conception rate was higher (P < 0.05) in cows treated with SMB early ( Day 11, 16 35 = 46% ). Cows that were difficult to inseminate had a lower (P < 0.01) conception rate (0 8 = 0% ) than cows that were normal (43 94 = 46% ) or easier than normal to inseminate (13 29 = 45% ).     

Synchronization of estrus and fertility in goats with norgestomet ear implants

Estrus was synchronized in 64 dairy goats in July with norgestomet ear implants. Half the does received ear implants that contained 6 mg norgestomet and the remaining does received implants that contained 3 mg. Implants were left in place for 11 days. Each doe received i.m. injections of 400 IU PMSG and 50 mug cloprostenol 24 hours prior to implant removal. Twenty-eight of 32 does (87.5%) that received 6 mg or 3 mg norgestomet exhibited onset of estrus within 24 hours of implant removal. All does had exhibited onset of standing estrus by 43 hours after implant removal. Does were hand-mated to fertile bucks twice daily while in standing estrus. There were no differences between does implanted with 6 mg or 3 mg in fertility to the induced estrus (74.2% vs 75% kidding), mean length of gestation (151.0 +/- 3.2 vs 151.6 +/- 2.0 days), mean number of kids per doe (2.1 +/- 0.8 vs 2.3 +/- 0.7) or in mean kid weights (3.10 +/- 0.80 vs 3.06 +/- 0.86 kg) (6 mg vs 3 mg, respectively). It was concluded that ear implants that contained 3 mg of norgestomet were equally as effective as implants that contained 6 mg for synchronization of estrus in dairy goats.     

Synchronization of estrus in beef heifers with a norgestomet implant and prostaglandin F2alpha

In a 5-year study (1973-1977), 281 cycling beef heifers were treated with a 7-day norgestomet (SC21009) ear implant and an intramuscular injection of prostaglandin F(2alpha) (PGF(2alpha)) at the time of implant removal or 24 hr before implant removal. Percentages of heifers in estrus by 36, 48, 60, 72, and 120 hr after implant removal were 32.4, 52.7, 71.6, 80.1, and 93.2, respectively. Onset of estrus occurred an average of 49.8 +/- 4.7 hr after treatment. Percentages of heifers in estrus 36 hr after treatment were 5.7 and 51.7 for those with a corpus luteum and those without a corpus luteum (or determined regressing by palpation) at implant removal, respectively. When PGF(2alpha) was injected 24 hr before implant removal, 55% of the heifers were in estrus by 36 hr after implant removal compared to 30% when PGF(2alpha) was injected at the time of implant removal; however, by 60 hr after implant removal the difference was 76% vs. 71%. First-service conception rates for synchronized and nonsynchronized heifers were 62.2% and 59.6%, respectively. During 1976 and 1977 heifers were checked for estrus every 4 hr and inseminated 2, 6, 10, 14, 18, 22, 26, or 30 hr after first detected to be in standing estrus. Conception rate was not significantly affected by time of insemination but tended to be higher for heifers bred 26 and 30 hr after first being detected in standing estrus (78.9% and 70.0% vs. average 59.2%). Treatment with a 7-day norgestomet implant plus a single injection of PGF(2alpha) 24 hr before or at implant removal appears to be a practical technique for synchronizing estrus in cycling heifers without affecting conception.     

Variable progesterone response and estradiol secretion in prepubertal beef heifers following treatment with norgestomet implants

Two experiments were conducted to determine the effects of norgestomet ear implants on progesterone response and estradiol secretion in prepubertal beef heifers. In the first experiment, 47 beef heifers were treated with norgestomet. The implants were implanted subcutaneously for 9 d. After implant removal, blood samples were taken from heifers 2 to 4 d per week for 40 d. Following progesterone determination in jugular venous plasma, heifers were classified according to their progesterone response: 1) no response (Group 1); no rise in progesterone above 1 ng/ml throughout the sampling period; 2) one cycle (Group 2); one increase in progesterone above 1 ng/ml for at least 2 d followed by no further increase in progesterone during the sampling period; and 3) two cycles (Group 3); a rise in progesterone above 1 ng/ml for at least 2 d followed by another cycle of normal duration. Heifers treated with norgestomet were classified as 23 with no response, 9 with 1 cycle and 15 with 2 cycles. Concentrations of estradiol were measured in jugular venous samples on Day 2 after implant removal. Mean concentrations of estradiol were greater in Group 3 than in Group 1 (P < or = 0.01). In Experiment 2, 29 prepubertal beef heifers were assigned randomly to either a 9-d treatment with norgestomet (n = 14) or to serve as untreated controls (n = 15). Blood plasma samples were collected daily from Days 0 to 44 after implant removal. After progesterone determination, heifers were classified as 8 with no response, 4 with 1 cycle and 3 with 2 cycles in the control group, and 5 with no response, 3 with 1 cycle and 6 with 2 cycles in the norgestomet group (frequencies did not differ; P > 0.1). Jugular venous blood plasma was also collected at 4-h intervals from 0 h to 96 h after implant removal and concentrations of estradiol were measured. Patterns of estradiol secretion differed (P < or = 0.05) and overall mean concentrations of estradiol over the first 96 h following implant removal were greater (P < or = 0.01) in norgestomet-treated heifers versus the controls. We conclude that norgestomet can produce a variable progesterone response with heifers with 2 cycles secreting more estradiol. Implants of norgestomet also causes more acute secretion of estradiol in prepubertal beef heifers.     

Role of luteal regression in embryo death in cattle

Inseminated crossbred beef cows and heifers were used in 2 experiments to investigate embryo survival after prostaglandin-induced or spontaneous luteal regression. In Experiment 1, luteal regression was induced by an intramuscular (im) injection of cloprostenol (500 mug) on Day 15 (day of ovulation = Day 0). Progestagen was replaced 24 or 36 h later either by one-and-a-half Syncro-Mate-B (SMB) ear implants (9 mg of norgestomet) and norgestomet solution (2.25 mg, im) containing no estradiol in 1 replicate or by 2 SMB implants (12 mg of norgestomet) and progesterone (100 mg, im) in the second replicate. Combined for both replicates, the Day-24 pregnancy rate in an untreated control group (Group 1, 16/19; 84%) was higher (P < 0.01) than in the 24-h group (Group 2, 9/20; 45%), which also was higher (P < 0.02) than in the 36-h group (Group 3, 3/23; 13%). In Experiment 2, 15 or 16 d after breeding, cattle with a corpus luteum at least 16 x 16 mm were given either 2 SMB implants or no treatment. At 24 to 26 d after breeding, pregnancy rates (48/65, 74% versus 49/68, 72%) were not significantly different, and all but 1 of the pregnant progestagen-supplemented cattle had a functional corpus luteum.     

Control of estrus and pregnancy in dairy heifers treated with Syncro-Mate-B

Control of estrus in dairy heifers with Syncro-Mate-B was evaluated in five experiments with a total of 393 Holstein heifers. Estradiol-17β at implant removal or gonadotropin releasing hormone 40 hr after implant removal did not cause any beneficial effect on fertility. In heifers implanted on selected days of the estrous cycle, 88.3% of heifers treated with SMB only were in estrus within 5 days of implant removal and fertility was not significantly different from that of control heifers. In heifers implanted at random stages of the estrous cycle, estrus occurred within 5 days of implant removal in 88.7% of 159 SMB treated heifers. First service conception rates (heifers pregnant of heifers inseminated) and pregnancy rates (heifers pregnant of heifers assigned) were 72.7% and 60.8% for heifers inseminated 8 to 16 hr after estrus within 5 days of implant removal, 55.0% and 55.0% for heifers inseminated 48 hr after implant removal without regard to estrus and 71.6% and 67.1% for control heifers inseminated over a 25 day period.     

Estrus and pregnancy after synchrony with lutalyse in conjunction with Syncro-Mate-B.

Estrous response and pregnancy rates are decreased for cows given Syncro-Mate-B (SMB) during metestrus (Day 1 to 5 of an estrous cycle). Data indicate these decreases are due, in part, to retention of a functional corpus luteum (CL). Our objective was to determine whether PGF2alpha administered in conjunction with SMB would improve estrous response and pregnancy rates in metestrous cows with no detrimental effects to cows in other stages of the estrous cycle. Three hundred seventy-three suckled beef cows were observed for estrus for 21 d before SMB administration to determine stage of an estrous cycle. Blood samples were collected 14 and 7 d before treatment and at SMB administration. Serum was assayed for concentration of progesterone to verify stage of estrous cycle or noncyclicity. All cows received the standard SMB regime and were allotted by age and stage of cycle to one of two groups. Cows denoted SMB + L received 25 mg of PGF2alpha 8 d after implantation, whereas cows denoted SMB served as controls. On Day 10, SMB implants were removed and females were observed for subsequent estrus. At this time, calves were removed from their dams for 48 h. Artificial insemination was performed 12 hr after observation of a standing estrus. Timed insemination was performed at 48 hr after implant removal for cows not inseminated at 24 or 36 hr after implant removal. Interval to synchronized estrus (within 5 d of implant removal) was lengthened for metestrous cows compared to cows in other stages of the cycle irrespective of treatment (P < 0.001). Cows receiving PGF2alpha had a greater pregnancy rate at 5 d compared to controls (P = .0672). Interval to estrus, estrous response, and pregnancy rate to A1 at d 28 or end of breeding season were not affected by administration of PGF2alpha in conjunction with SMB when compared to the standard SMB protocol.     

Synchronization of estrus and fertility in zebu beef heifers treated with three estrus synchronization protocols

The effects on estrus and fertility of 3 estrus synchronization protocols were studied in Brahman beef heifers. In Treatment 1 (PGF protocol; n=234), heifers received 7.5 mg, i.m. prostianol on Day 0 and were inseminated after observed estrus until Day 5. Treatment 2 (10-d NOR protocol; n = 220) consisted of norgestomet (NOR; 3 mg, s.c. implant and 3 mg, i.m.) and estradiol valerate (5 mg, i.m.) treatment on Day -10, NOR implant removal and 400 IU, i.m. PMSG on Day 0, and AI after observed estrus through to Day 5. Treatment 3 (14-d NOR+PGF protocol; n = 168) constituted a NOR implant (3 mg, sc) on Day -14, NOR implant removal on Day 0, PGF on Day 16, and AI after observed estrus through to Day 21. All heifers were examined for return to estrus at the next cycle and inseminated after observed estrus. The heifers were then exposed to bulls for at least 21 d. During the period of estrus observation (5 d) after treatment, those heifers treated with the PGF protocol had a lower (P<0.01) rate of estrual response (58%) than heifers treated with the 10-d NOR (87%) or 14-d NOR+PGF (88%) protocol. Heifers treated with the 10-d NOR protocol displayed estrus earlier and had a closer synchrony of estrus than heifers treated with either the PGF or the 14-d NOR+PGF protocol. Heifers treated with the 14-d NOR+PGF protocol had higher (P<0.05) conception and calving rates (51 and 46%) to AI at the induced estrus than heifers treated with the PGF (45 and 27%) or the 10-d NOR (38 and 33%) protocol. Calving rate to 2 rounds of AI was greater (P<0.05) for heifers treated with the 14-d NOR-PGF (50%) protocol than heifers treated with the 10-d NOR (38%) but not the PGF (43%) protocol. Breeding season calving rates were similar among the 3 protocols. The results show that the 14-d NOR+PGF estrus synchronization protocol induced a high incidence of estrus with comparatively high fertility in Brahman heifers.     

Estrus synchronization and pregnancy rates in cyclic and noncyclic beef cows and heifers treated with syncro-mate B or Norgestomet and Alfaprostol

Postpartum lactating cows (N=118) and virgin heifers (N=60) were treated with subcutaneous Norgestomet implants for nine days and received either an intramuscular injection (im) of 5 mg estradiol valerate and 3 mg Norgestomet at the time of implant insertion or an im injection of 5 mg Alfaprostol 24 hr before implant removal. Animals were artificially inseminated 12 hr after detection of estrus. Of the cows and heifers, 78% and 88%, respectively, were in estrus within five days after implant removal (P<0.09). There was no difference between treatments in the proportion of animals in estrus or in the timing of estrus (P<0.85). Estrus was detected in a greater (P<0.05) proportion of animals that were cyclic prior to treatment (88%) than among those that were anestrous prior to treatment (77%). Pregnancy rates after five days were similar between heifers that were cyclic (42%) or anestrous (47%) prior to treatment; however, the five-day pregnancy rate in cows that were anestrous prior to treatment was 38% lower than that in cows that were cyclic prior to treatment (17 vs 55%, P<0.01). Although the treatments synchronized or induced estrus in both cyclic and anestrous animals, marked variability in estrous response and fertility among previously cyclic or anestrous postpartum cows limited the effectiveness of the treatments.